Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau(Institut Paoli-Calmettes), Simon J. Harrison(The University of Melbourne), Thierry Façon(Inserm), Shaji Kumar(Mayo Clinic in Arizona), Sari H. Enschede(AbbVie (United States)), Andrew W. Roberts(Walter and Eliza Hall Institute of Medical Research), Ahmed Hamed Salem(Ain Shams University), Jeremy A. Ross(AbbVie (United States)), Kevin J. Freise(AbbVie (United States)), Cyrille Touzeau(Hotel Dieu Hospital), Wijith Munasinghe(AbbVie (United States)), Joel D. Leverson(AbbVie (United States)), Paulo Maciag(AbbVie (United States)), Jia Jia(China Medical University), Amit B. Agarwal(University of Arizona), Jaclyn Cordero(AbbVie (United States)), Elizabeth A. Punnoose(University Hospital Cologne), Maria Verdugo(AbbVie (United States)), Asher Chanan‐Khan(WinnMed)
Cited by 271
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2016|1.1k